Cochrane review: evidence too weak to support methadone for neuropathic pain

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
Takeaway
  • The evidence is too weak to draw conclusions about the value of methadone in treating neuropathic pain, according to a Cochrane review.
Why this matters
  • The prevalence of neuropathic pain is 7%-10% of the general population, and it is difficult to treat.
Study design
  • This was a systematic review of 3 randomized controlled trials (n=105) that met eligibility criteria after a search of CENTRAL, MEDLINE, EMBASE and 2 clinical trial registries.
  • Funding: Saltonstall Fund for Pain Research; the National Institute for Health Research.
Key findings
  • The 3 trials had high risk for bias from incomplete recordi...